(Q43687680)

25 November 2017

Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients (English)

1 reference

25 November 2017

1 reference

1 reference

1 reference

4

1 reference

25 November 2017

Asnis GM

1

1 reference

25 November 2017

Hameedi FA

2

1 reference

25 November 2017

Goddard AW

3

1 reference

25 November 2017

Black D

5

1 reference

25 November 2017

Jameel M

6

1 reference

25 November 2017

Desagani K

7

1 reference

25 November 2017

Woods SW

8

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

25 November 2017

1 reference

25 November 2017

103

1 reference

25 November 2017

1-14

1 reference

25 November 2017

1

1 reference

Management of Panic Disorders

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

The use of the Panic and Agoraphobia Scale in a clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Panic disorder and suicidal ideation and behavior: discrepant findings in psychiatric outpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Predictors of short-term treatment response in 66 patients with panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Clomipramine for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Noradrenergic function and the mechanism of action of antianxiety treatment. II. The effect of long-term imipramine treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Noradrenergic function and the mechanism of action of antianxiety treatment. I. The effect of long-term alprazolam treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. A double-blind comparison of zimeldine, imipramine and placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Serotonin and anxiety revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Depression in patients receiving lorazepam for panic.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Panic attacks. A neurochemical overview of models and mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Sertraline in the treatment of panic disorder: a double-blind multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Fluvoxamine attenuates panic induced by 35% CO2 challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

The effect of personality on placebo response in panic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Fluvoxamine or Placebo in the Treatment of Panic Disorder and Relationship to Blood Concentrations of Fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Multicenter collaborative panic disorder severity scale

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

The Clinical Anxiety Scale: an instrument derived from the Hamilton Anxiety Scale

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Review of fluvoxamine safety database

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Suicidal ideation and suicide attempts in panic disorder and attacks.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2801%2900265-7

7 January 2021

10.1016/S0165-1781(01)00265-7

Identifiers

DOI

1 reference

25 November 2017

1 reference